I-Corps: Customer discovery for silicon nanowire biosensor

I-Corps：硅纳米线生物传感器的客户发现

• 批准号: 1643115
• 负责人: Fatima Toor
• 金额: $ 5万
• 依托单位: University of Iowa
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-01 至 2018-01-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1643115&HistoricalAwards=false
• 关键词: Corps; Customer; discovery; silicon; nanowire

The commercial potential of this I-Corps project will be that it will further develop a sensor to detect lung cancer without a bioposy and to give more specific diagnostics for this cancer thus enabling targeted drug therapy. This will decrease the cost for treating cancer, improving survival rates of lung cancer, and provide less invasive and more accurate diagnostics. The technology is a platform technology to enable low cost effective tests for all diseases that cause the body to release neoantigens, anti-bodies, or DNA mutations. The developed sensor is more sensitive than existing sensors and will be able to detect the type of cancer in the blood of patients that have cancer. This will potentially allow doctors to prescribe targeted drug therapy and will be able to detect cancer earlier, target a patient's cancer without needing a biopsy, and potentially lead to a higher survival rate.This I-Corps project will explore the commercial potential of a nanowire biosensor platform that is more sensitive than existing sensors and will be able to detect a type of lung cancer in the blood of patients. The nanowire biosensor platform is able to measure DNA at high sensitivities because it uses nanowires that have a very high surface area and are sensitive to the atmosphere around them. The proposed platform technology utilizes arrays of vertically aligned nanowires. Using this device design, sensors with over a million nanowires per sensor have been developed by the team. The biosensor has been used for prostate specific antigen (PSA) detection and have positive preliminary results. This new method of detection enables sensors with nanowire arrays versus a single nanowire, resulting in higher sensitivity devices.

这个I-Corps项目的商业潜力在于，它将进一步开发一种传感器，在不进行生物活检的情况下检测肺癌，并对这种癌症进行更具体的诊断，从而实现靶向药物治疗。 这将降低治疗癌症的成本，提高肺癌的存活率，并提供更少的侵入性和更准确的诊断。该技术是一种平台技术，可以对导致身体释放新抗原，抗体或DNA突变的所有疾病进行低成本有效的测试。开发的传感器比现有传感器更灵敏，将能够检测癌症患者血液中的癌症类型。 这将有可能使医生处方靶向药物治疗，并将能够更早地检测癌症，靶向患者的癌症而不需要活检，并有可能导致更高的生存率。这个I-Corps项目将探索纳米线生物传感器平台的商业潜力，该平台比现有的传感器更敏感，并将能够检测患者血液中的一种肺癌。纳米线生物传感器平台能够以高灵敏度测量DNA，因为它使用的纳米线具有非常高的表面积，并且对周围的大气敏感。所提出的平台技术利用垂直对齐的纳米线阵列。 使用这种设备设计，该团队开发了每个传感器具有超过一百万个纳米线的传感器。该传感器已用于前列腺特异性抗原（PSA）的检测，并取得了积极的初步结果。这种新的检测方法使传感器具有纳米线阵列而不是单个纳米线，从而产生更高灵敏度的设备。